Bimagrumab
About
About Bimagrumab
Bimagrumab is a human monoclonal antibody that blocks activin type II receptors (ActRII), inhibiting myostatin and related ligands to simultaneously increase muscle mass and reduce fat mass — a unique dual body composition effect. In a Phase II trial of diabetic patients, bimagrumab reduced fat mass by 20.5% and increased lean mass by 3.6% over 48 weeks. It is being studied in combination with semaglutide to preserve muscle during GLP-1-driven weight loss.
Science
Mechanism of Action
Binds and blocks activin type IIA and IIB receptors, preventing myostatin and activin signaling that normally suppresses muscle growth; simultaneously promotes adipose tissue browning and fat oxidation through ActRII-dependent pathways.
Dosing
Typical Protocol
10 mg/kg IV infusion every 4 weeks in clinical trials; subcutaneous formulation under development.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Regulatory
Legal Status in 2026
This compound occupies a regulatory grey area in 2026. It is neither explicitly FDA-approved nor clearly illegal for personal use, but it lacks formal clinical approval and may not be legally sold for human use in all contexts. Proceed with caution: source quality is variable, and regulatory status can change. Always consult a physician.
Evidence
Evidence Tier
Evidence from randomized controlled trials (RCTs) or large observational studies in humans. This is the gold standard — effects have been measured in controlled conditions and results are peer-reviewed and reproducible.
No verified providers offering Bimagrumab yet
We audit new providers every week. Leave your email and we’ll let you know as soon as a Vial-verified provider starts offering Bimagrumab.
Free. We’ll only email when there’s a real match.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.